Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

@article{Kantarjian2012MulticenterRO,
  title={Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.},
  author={Hagop M Kantarjian and X. Thomas and Anna Dmoszyńska and Agnieszka Wierzbowska and Grzegorz Mazur and Jiř{\'i} Mayer and J V Gau and W H Chou and Rena Buckstein and Jaroslav {\vC}erm{\'a}k and Ching-yuan Kuo and Albert Oriol and Farhad Ravandi and Stefan H Faderl and Jacques Delaunay and Daniel B. Lysak and M. L. Minden and Christopher Arthur},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 21},
  pages={2670-7}
}
PURPOSE This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics. PATIENTS AND METHODS Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive decitabine 20 mg/m(2) per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks or TC (supportive care or cytarabine 20 mg/m(2… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 230 extracted citations

Similar Papers

Loading similar papers…